• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ASK1(丝裂原活化蛋白激酶激酶激酶5)作为12q14-q15和6q23扩增的恶性纤维组织细胞瘤的潜在治疗靶点。

ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications.

作者信息

Chibon Frédéric, Mariani Odette, Derré Josette, Mairal Aline, Coindre Jean-Michel, Guillou Louis, Sastre Xavier, Pédeutour Florence, Aurias Alain

机构信息

INSERM U509, Molecular Pathology of Cancers, Institut Curie, Paris, France.

出版信息

Genes Chromosomes Cancer. 2004 May;40(1):32-7. doi: 10.1002/gcc.20012.

DOI:10.1002/gcc.20012
PMID:15034865
Abstract

Malignant fibrous histiocytomas (MFHs) are aggressive tumors without any definable line of differentiation. We recently demonstrated that about 20% of them are characterized by high-level amplifications of the 12q14-q15 chromosome region, associated with either 1p32 or 6q23 band amplification. This genetic finding, very similar to that in well-differentiated liposarcomas, strongly suggests that these tumors actually correspond to undifferentiated liposarcomas. It also suggests that the lack of differentiation could be the consequence of amplification of target genes localized in the 1p32 or 6q23 bands. We report here the characterization by array CGH of the 6q23 minimal region of amplification. Our findings demonstrate that amplification and overexpression of ASK1 (MAP3K5), a gene localized in the 6q23 band and encoding a mitogen-activated protein kinase kinase kinase of the JNK-MAPK signaling pathway, could inhibit the adipocytic differentiation process of the tumor cells. Treatment of a cell line with specific inhibitors of ASK1 protein resulted in the bypass of the differentiation block and induction of a strong adipocytic differentiation. These observations indicate that ASK1 is a target for new therapeutic management of these aggressive tumors.

摘要

恶性纤维组织细胞瘤(MFH)是一种侵袭性肿瘤,没有任何明确的分化谱系。我们最近证明,其中约20%的肿瘤具有12q14-q15染色体区域的高水平扩增,与1p32或6q23带扩增相关。这一遗传学发现与高分化脂肪肉瘤非常相似,强烈提示这些肿瘤实际上相当于未分化脂肪肉瘤。这也表明缺乏分化可能是位于1p32或6q23带的靶基因扩增的结果。我们在此报告通过阵列比较基因组杂交(array CGH)对6q23最小扩增区域的特征分析。我们的研究结果表明,ASK1(MAP3K5)基因的扩增和过表达可抑制肿瘤细胞的脂肪细胞分化过程,ASK1基因位于6q23带,编码JNK-MAPK信号通路的丝裂原活化蛋白激酶激酶激酶。用ASK1蛋白特异性抑制剂处理细胞系导致分化阻滞的解除并诱导强烈的脂肪细胞分化。这些观察结果表明,ASK1是这些侵袭性肿瘤新治疗策略的一个靶点。

相似文献

1
ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications.ASK1(丝裂原活化蛋白激酶激酶激酶5)作为12q14-q15和6q23扩增的恶性纤维组织细胞瘤的潜在治疗靶点。
Genes Chromosomes Cancer. 2004 May;40(1):32-7. doi: 10.1002/gcc.20012.
2
Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization.基于高分辨率寡核苷酸阵列比较基因组杂交技术评估高分化/去分化脂肪肉瘤。
Genes Chromosomes Cancer. 2011 Feb;50(2):95-112. doi: 10.1002/gcc.20835.
3
A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas.
Cancer Genet Cytogenet. 2002 Nov;139(1):24-9. doi: 10.1016/s0165-4608(02)00614-3.
4
Characterization of the 12q amplicons by high-resolution, oligonucleotide array CGH and expression analyses of a novel liposarcoma cell line.通过高分辨率寡核苷酸阵列比较基因组杂交技术对12q扩增子进行表征以及对一种新型脂肪肉瘤细胞系进行表达分析。
Cancer Lett. 2008 Feb 18;260(1-2):37-47. doi: 10.1016/j.canlet.2007.10.032. Epub 2007 Dec 21.
5
Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity.炎症性恶性纤维组织细胞瘤和去分化脂肪肉瘤:组织学回顾、基因组概况以及MDM2和CDK4状态支持单一实体。
J Pathol. 2004 Jul;203(3):822-30. doi: 10.1002/path.1579.
6
c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme.c-Jun基因扩增和过表达在脂肪肉瘤中具有致癌性,但并不总是足以抑制脂肪细胞分化程序。
J Pathol. 2009 Jul;218(3):292-300. doi: 10.1002/path.2564.
7
Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma.大多数发生于腹膜后的恶性纤维组织细胞瘤为去分化脂肪肉瘤:25例最初诊断为恶性纤维组织细胞瘤的病例回顾
Mod Pathol. 2003 Mar;16(3):256-62. doi: 10.1097/01.MP.0000056983.78547.77.
8
Characterization of large chromosome markers in a malignant fibrous histiocytoma by spectral karyotyping, comparative genomic hybridization (CGH), and array CGH.
Cancer Genet Cytogenet. 2004 Apr 1;150(1):27-32. doi: 10.1016/j.cancergencyto.2003.08.009.
9
JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas.JUN癌基因扩增和过表达会阻碍高侵袭性肉瘤中的脂肪细胞分化。
Cancer Cell. 2007 Apr;11(4):361-74. doi: 10.1016/j.ccr.2007.02.007.
10
Establishment of a novel human dedifferentiated liposarcoma cell line, FU-DDLS-1: conventional and molecular cytogenetic characterization.新型人去分化脂肪肉瘤细胞系FU-DDLS-1的建立:传统及分子细胞遗传学特征分析
Int J Oncol. 2003 Mar;22(3):535-42.

引用本文的文献

1
Updated insights on ASK1 signaling: mechanisms, regulation, and therapeutic potential in diseases.关于ASK1信号传导的最新见解:疾病中的机制、调控及治疗潜力
Mol Cell Biochem. 2025 Jun 14. doi: 10.1007/s11010-025-05330-y.
2
Cellular origin and clonal evolution of human dedifferentiated liposarcoma.人类去分化脂肪肉瘤的细胞起源和克隆进化。
Nat Commun. 2024 Sep 12;15(1):7941. doi: 10.1038/s41467-024-52067-1.
3
Detection of MDM2 amplification by shallow whole genome sequencing of cell-free DNA of patients with dedifferentiated liposarcoma.
应用游离细胞 DNA 浅层全基因组测序检测去分化脂肪肉瘤患者 MDM2 扩增。
PLoS One. 2022 Jan 5;17(1):e0262272. doi: 10.1371/journal.pone.0262272. eCollection 2022.
4
Biology and Management of Dedifferentiated Liposarcoma: State of the Art and Perspectives.去分化脂肪肉瘤的生物学特性与管理:现状与展望
J Clin Med. 2021 Jul 22;10(15):3230. doi: 10.3390/jcm10153230.
5
Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma.平滑肌肉瘤和脂肪肉瘤的基因组进化模式。
Clin Cancer Res. 2019 Aug 15;25(16):5135-5142. doi: 10.1158/1078-0432.CCR-19-0271. Epub 2019 Jun 4.
6
Clinical and Molecular Spectrum of Liposarcoma.脂肪肉瘤的临床与分子谱。
J Clin Oncol. 2018 Jan 10;36(2):151-159. doi: 10.1200/JCO.2017.74.9598. Epub 2017 Dec 8.
7
The Epstein-Barr Virus-encoded miR-BART22 targets MAP3K5 to promote host cell proliferative and invasive abilities in nasopharyngeal carcinoma.爱泼斯坦-巴尔病毒编码的miR-BART22靶向丝裂原活化蛋白激酶激酶激酶5,以促进鼻咽癌宿主细胞的增殖和侵袭能力。
J Cancer. 2017 Jan 25;8(2):305-313. doi: 10.7150/jca.15753. eCollection 2017.
8
Liposarcoma: molecular targets and therapeutic implications.脂肪肉瘤:分子靶点与治疗意义
Cell Mol Life Sci. 2016 Oct;73(19):3711-8. doi: 10.1007/s00018-016-2266-2. Epub 2016 May 12.
9
Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas.HMGA2、CDK4 和 JUN 扩增在高分化和去分化脂肪肉瘤中的预后价值。
Mod Pathol. 2015 Nov;28(11):1404-14. doi: 10.1038/modpathol.2015.96. Epub 2015 Sep 4.
10
Expression of apoptosis signal-regulating kinase 1 is associated with tight junction protein claudin-6 in cervical carcinoma.凋亡信号调节激酶1的表达与宫颈癌中的紧密连接蛋白claudin-6相关。
Int J Clin Exp Pathol. 2015 May 1;8(5):5535-41. eCollection 2015.